How to facilitate development of cancer treatment based on genetically modified T-cells
Watch live broadcast of expert discussion at EMA
A workshop on the scientific and regulatory challenges of innovative cancer immunotherapy medicines based on genetically modified T-cells (white blood cells that normally fight off viruses and bacteria) will take place at the European Medicines Agency (EMA) on Tuesday and Wednesday, 15-16 November 2016.
You can follow a live broadcast of the workshop by clicking on the 'multimedia' tab on the event page.
The workshop, which is organised by the Agency’s Committee for Advanced Therapies(CAT), aims to facilitate dialogue between the CAT and medicine developers from industry and academia on current scientific developments, regulatory requirements for product manufacture and clinical development of these medicines.
Immunotherapy is a type of cancer treatment that mobilises the body's own defence mechanisms to fight the cancer. Immunotherapy medicines have significantly improved the therapeutic landscape for patients with certain cancers, such as lung cancer or melanoma.
T-cell based immunotherapy is an innovative approach where T-cells from a patient’s blood are genetically engineered in a laboratory to allow them to recognise cancer cells through specific receptor proteins. In the body of a patient, these so called Chimeric Antigen Receptor (CAR) T-cells can then identify and destroy cancer cells.
CAR T-cell medicines are being developed and are currently being tested in clinical trialsin a variety of cancers. However, there are still many scientific and regulatory challenges to be overcome before these innovative products can be brought to the market for the benefit of patients.
For more information please see the agenda of the workshop.
Presentations and a video recording of the event will be published after the workshop.
- Committee for Advanced Therapies (CAT) workshop: scientific and regulatory challenges of genetically modified cell-based cancer immunotherapy products (15-16/11/2016)
- Committee for Advanced Therapies (CAT)
- Programme of the Committee for Advanced Therapies (CAT) workshop: scientific and regulatory challenges of genetically modified cell-based cancer immunotherapy products (08/11/2016)
Latest News from
Security Union: EC presents new measures to better protect EU citizens19/10/2017 14:27:00
The EC has presented alongside its 11th Security Union Report a set of operational and practical measures to better defend EU citizens against terrorist threats and deliver a Europe that protects.
EU-U.S. Privacy Shield: First review shows it works but implementation can be improved19/10/2017 13:10:00
The EC has published its first annual report on the functioning of the EU- U.S. Privacy Shield, the aim of which is to protect the personal data of anyone in the EU transferred to companies in the U.S. for commercial purposes.
EC opens in-depth investigation into proposed merger of Celanese's and Blackstone's acetate tow activities18/10/2017 16:15:00
The EC has opened an in-depth investigation to assess the proposed creation of an acetate flake and acetate tow joint venture by Celanese and Blackstone under the EU Merger Regulation.
EU approves €100m in financial assistance for Jordan18/10/2017 14:10:00
The EC, on behalf of the EU, has approved the disbursement of a €100m loan to Jordan under its Macro-Financial Assistance (MFA) programme.